Next Article in Journal
Arsenic Trioxide, Itraconazole, All-Trans Retinoic Acid and Nicotinamide: A Proof of Concept for Combined Treatments with Hedgehog Inhibitors in Advanced Basal Cell Carcinoma
Next Article in Special Issue
Varespladib Inhibits the Phospholipase A2 and Coagulopathic Activities of Venom Components from Hemotoxic Snakes
Previous Article in Journal
Free Fatty Acid Receptors 2 and 3 as Microbial Metabolite Sensors to Shape Host Health: Pharmacophysiological View
Previous Article in Special Issue
Caterpillar Venom: A Health Hazard of the 21st Century
Open AccessArticle

Characterization of Synthetic Tf2 as a NaV1.3 Selective Pharmacological Probe

Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia
Institute of Physiology, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany
Research Training Group 2416 MultiSenses-MultiScales, RWTH Aachen University, 52074 Aachen, Germany
Research Training Group 2415 ME3T, RWTH Aachen University, 52074 Aachen, Germany
School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia
Authors to whom correspondence should be addressed.
Biomedicines 2020, 8(6), 155;
Received: 15 May 2020 / Revised: 2 June 2020 / Accepted: 5 June 2020 / Published: 11 June 2020
(This article belongs to the Special Issue Animal Venoms–Curse or Cure?)
NaV1.3 is a subtype of the voltage-gated sodium channel family. It has been implicated in the pathogenesis of neuropathic pain, although the contribution of this channel to neuronal excitability is not well understood. Tf2, a β-scorpion toxin previously identified from the venom of Tityus fasciolatus, has been reported to selectively activate NaV1.3. Here, we describe the activity of synthetic Tf2 and assess its suitability as a pharmacological probe for NaV1.3. As described for the native toxin, synthetic Tf2 (1 µM) caused early channel opening, decreased the peak current, and shifted the voltage dependence of NaV1.3 activation in the hyperpolarizing direction by −11.3 mV, with no activity at NaV1.1, NaV1.2, and NaV1.4-NaV1.8. Additional activity was found at NaV1.9, tested using the hNav1.9_C4 chimera, where Tf2 (1 µM) shifted the voltage dependence of activation by −6.3 mV. In an attempt to convert Tf2 into an NaV1.3 inhibitor, we synthetized the analogue Tf2[S14R], a mutation previously described to remove the excitatory activity of related β-scorpion toxins. Indeed, Tf2[S14R](10 µM) had reduced excitatory activity at NaV1.3, although it still caused a small −5.8 mV shift in the voltage dependence of activation. Intraplantar injection of Tf2 (1 µM) in mice caused spontaneous flinching and swelling, which was not reduced by the NaV1.1/1.3 inhibitor ICA-121431 nor in NaV1.9-/- mice, suggesting off-target activity. In addition, despite a loss of excitatory activity, intraplantar injection of Tf2[S14R](10 µM) still caused swelling, providing strong evidence that Tf2 has additional off-target activity at one or more non-neuronal targets. Therefore, due to activity at NaV1.9 and other yet to be identified target(s), the use of Tf2 as a selective pharmacological probe may be limited. View Full-Text
Keywords: Tf2; sodium channel; NaV1.3; NaV1.9; scorpion; toxin Tf2; sodium channel; NaV1.3; NaV1.9; scorpion; toxin
Show Figures

Figure 1

MDPI and ACS Style

Israel, M.R.; Dash, T.S.; Bothe, S.N.; Robinson, S.D.; Deuis, J.R.; Craik, D.J.; Lampert, A.; Vetter, I.; Durek, T. Characterization of Synthetic Tf2 as a NaV1.3 Selective Pharmacological Probe. Biomedicines 2020, 8, 155.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop